View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 13, 2018updated 23 Mar 2018 3:04pm

TaiMed’s Trogarza to have large impact on HIV treatment

Taiwanese company TaiMed Biologics has developed Trogarza, a new class of HIV therapeutic that represents the first innovator drug in this disease area in 10 years.

By GBI Research

Taiwanese company TaiMed Biologics has developed Trogarza, a new class of HIV therapeutic that represents the first innovator drug in this disease area in 10 years.

Trogarza is a humanised monoclonal antibody, and gained FDA approval in March 2018. It works by preventing the HIV virus from infecting the host’s cells, through the binding of receptors on the surface of CD4+ T cells.

The drug has been shown to work with patients who are resistant to current therapies, and is therefore likely to play an essential role in the last line of therapeutics.

Collaboration for marketing

TaiMed biologics has 12 years of marketing exclusivity for Trogarza, and has also entered into deals with Theratechnologies. The first of these deals gave Theratechnologies exclusive distribution and marketing rights in North America. It paid $1 million up front, with a further $1 million to be paid once Trogarza reaches the market, and further milestone payments integrated into the deal.

In 2017 another deal was signed giving Theratechnologies the rights for Trogarza for European regions.

WuXi Biologics are responsible for production of Trogarza, and all three companies have seen their share prices increase since the FDA approval. Sales of Trogarza are predicted reach $67 million in 2018, and $566 million by 2023. It is expected to be a major product in the fight against HIV, and a strong first marketed drug for TaiMed.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU